JP2012521786A - インフルエンザウイルスワクチン及びその使用 - Google Patents

インフルエンザウイルスワクチン及びその使用 Download PDF

Info

Publication number
JP2012521786A
JP2012521786A JP2012503612A JP2012503612A JP2012521786A JP 2012521786 A JP2012521786 A JP 2012521786A JP 2012503612 A JP2012503612 A JP 2012503612A JP 2012503612 A JP2012503612 A JP 2012503612A JP 2012521786 A JP2012521786 A JP 2012521786A
Authority
JP
Japan
Prior art keywords
influenza
seq
virus
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012503612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521786A5 (enExample
Inventor
シー． ロウエン アニセ
ステエル ジョフン
ガルシアサストレ アドルフォ
パレセ ペテル
Original Assignee
モウント シナイ スクール オフ メディシネ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モウント シナイ スクール オフ メディシネ filed Critical モウント シナイ スクール オフ メディシネ
Publication of JP2012521786A publication Critical patent/JP2012521786A/ja
Publication of JP2012521786A5 publication Critical patent/JP2012521786A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012503612A 2009-03-30 2010-03-30 インフルエンザウイルスワクチン及びその使用 Withdrawn JP2012521786A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16489609P 2009-03-30 2009-03-30
US61/164,896 2009-03-30
US29908410P 2010-01-28 2010-01-28
US61/299,084 2010-01-28
PCT/US2010/029202 WO2010117786A1 (en) 2009-03-30 2010-03-30 Influenza virus vaccines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016113966A Division JP2016199557A (ja) 2009-03-30 2016-06-08 インフルエンザウイルスワクチン及びその使用

Publications (2)

Publication Number Publication Date
JP2012521786A true JP2012521786A (ja) 2012-09-20
JP2012521786A5 JP2012521786A5 (enExample) 2013-05-16

Family

ID=42359461

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012503612A Withdrawn JP2012521786A (ja) 2009-03-30 2010-03-30 インフルエンザウイルスワクチン及びその使用
JP2016113966A Withdrawn JP2016199557A (ja) 2009-03-30 2016-06-08 インフルエンザウイルスワクチン及びその使用
JP2018089627A Pending JP2018134107A (ja) 2009-03-30 2018-05-08 インフルエンザウイルスワクチン及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016113966A Withdrawn JP2016199557A (ja) 2009-03-30 2016-06-08 インフルエンザウイルスワクチン及びその使用
JP2018089627A Pending JP2018134107A (ja) 2009-03-30 2018-05-08 インフルエンザウイルスワクチン及びその使用

Country Status (6)

Country Link
US (2) US9051359B2 (enExample)
EP (2) EP2413962A1 (enExample)
JP (3) JP2012521786A (enExample)
AU (2) AU2010234849B2 (enExample)
CA (1) CA2787099A1 (enExample)
WO (1) WO2010117786A1 (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526849A (ja) * 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP2016508133A (ja) * 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
JP2016531590A (ja) * 2013-09-18 2016-10-13 レヴィセプト エルティーディーＬｅｖｉｃｅｐｔ Ｌｔｄ 融合タンパク質
JP2016199557A (ja) * 2009-03-30 2016-12-01 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
JP2017527303A (ja) * 2014-07-17 2017-09-21 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
JP2019516374A (ja) * 2016-05-19 2019-06-20 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン がんの腫瘍崩壊療法のためのｖｓｖ／ｎｄｖハイブリッドウイルス
US10544207B2 (en) 2013-03-14 2020-01-28 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
JPWO2019124557A1 (ja) * 2017-12-21 2021-01-28 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2022071492A1 (ja) * 2020-09-30 2022-04-07 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物
JP2023539771A (ja) * 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
KR20100120157A (ko) 2007-11-27 2010-11-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
US20100040635A1 (en) * 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
EP2536428B1 (en) 2010-02-18 2018-12-05 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
AU2011261396B2 (en) 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
US9060972B2 (en) * 2010-10-30 2015-06-23 George Dacai Liu Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
AU2012212463B2 (en) * 2011-01-31 2016-07-07 Nanotherapeutics, Inc. Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
LT3418300T (lt) 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
AU2012289926A1 (en) * 2011-08-03 2014-03-13 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
WO2013043729A1 (en) * 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2013044203A2 (en) * 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
TWI700368B (zh) 2011-09-30 2020-08-01 苜蓿股份有限公司 增加植物類病毒顆粒產率
CN104066446B (zh) * 2011-11-28 2017-10-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
US20130315955A1 (en) * 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US9550813B2 (en) 2012-05-22 2017-01-24 The Board Of Trustees Of The Leland Stanford Junior University Disulfide stabilized foldon polypeptides
JP2015519348A (ja) * 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
RU2545695C2 (ru) * 2012-07-17 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт экспериментальной медицины" Северо-Западного отделения Российской академии медицинских наук (ФГБУ "НИИЭМ" СЗО РАМН) Вакцинный штамм вируса гриппа в/60/висконсин/2010/125
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
IL295155A (en) * 2013-03-28 2022-09-01 Medicago Inc Production of influenza virus-like particles in plants
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
AU2014273173B2 (en) * 2013-05-30 2018-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US20160258005A1 (en) * 2013-07-02 2016-09-08 The Trustees Of The University Of Pennsylvania Methods for rapid ribonucleic acid fluorescence in situ hybridization
EP3027640B1 (en) 2013-08-03 2018-03-07 Avatar Medical, LLC Influenza hemagglutinin proteins and methods of use thereof
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
TWI714522B (zh) 2014-01-10 2021-01-01 加拿大商苜蓿股份有限公司 Cpmv強化子元件
EP3137487B1 (en) 2014-05-01 2021-03-03 Indian Institute of Science Polypeptides for generating anti-influenza antibodies and uses thereof
PE20170291A1 (es) * 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
EP3166962B1 (en) 2014-07-10 2019-08-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2016109792A2 (en) 2014-12-31 2016-07-07 The Usa, As Represented By The Secretary, Detp. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
WO2017123652A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
WO2018013704A1 (en) 2016-07-12 2018-01-18 Duke University Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
IL303650B2 (en) 2016-09-02 2025-02-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
EP3939604A3 (en) * 2016-10-21 2022-06-22 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
AU2017386682A1 (en) 2016-12-28 2019-07-25 Invvax, Inc. Influenza vaccines
KR20200090143A (ko) 2017-08-21 2020-07-28 다이아딕 인터내셔널 (유에스에이), 인크. 마이셀리오프쏘라 써모필라에서 독감 백신의 생산
WO2019070955A1 (en) 2017-10-04 2019-04-11 Georgia State University Research Foundation, Inc. INFLUENZA VACCINE COMPRISING HAEMAGGLUTIN WITHOUT HEAD
EP3713600A4 (en) 2017-11-22 2021-08-11 Her Majesty The Queen In Right of Canada as represented by The Minister of Health SYNTHETIC HEMAGGLUTININ AS A UNIVERSAL VACCINE AGAINST INFECTION BY TYPE B INFLUENZA VIRUSES (IBV)
HRP20220980T1 (hr) 2018-01-23 2022-11-11 Janssen Vaccines & Prevention B.V. Cjepiva protiv virusa influence i njihova uporaba
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
KR102714626B1 (ko) 2018-06-12 2024-10-08 케이바이오 홀딩스 리미티드 바이러스 및 항원 정제 및 접합
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US12419946B2 (en) 2019-02-07 2025-09-23 Duke University Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
EP3976095A1 (en) 2019-06-02 2022-04-06 Pentavalent Bio Sciences PVT Ltd. Live attenuated universal influenza virus vaccines, methods and uses thereof
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
US20210325367A1 (en) * 2020-04-20 2021-10-21 Satish Mahna Controlled Exposure to Pathogens for Generating Immunity
WO2022020460A1 (en) * 2020-07-21 2022-01-27 Flugen, Inc. Vaccine using m2/bm2-deficient influenza vectors
WO2022087127A1 (en) * 2020-10-20 2022-04-28 Duke University Replication incompetent influenza vaccine platform for foreign protein delivery
EP4456915A1 (en) * 2021-12-31 2024-11-06 Mynvax Private Limited Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4693981A (en) 1983-12-20 1987-09-15 Advanced Genetics Research Institute Preparation of inactivated viral vaccines
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5182192A (en) 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
JP3037554B2 (ja) 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
EP0621339B1 (en) 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
US5674703A (en) 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
WO1996011279A2 (en) 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
WO1997040177A1 (en) 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
WO1997040161A1 (en) * 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
KR100894670B1 (ko) 1996-07-15 2009-04-22 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포융합 바이러스 백신의 생산
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
CN1232504A (zh) 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
KR100663319B1 (ko) 1997-04-14 2007-01-02 마이크로메트 에이지 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998053078A1 (en) 1997-05-23 1998-11-26 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
ATE361973T1 (de) 1997-07-11 2007-06-15 Univ Yale Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
PT1085904E (pt) 1998-06-12 2013-03-05 Sinai School Medicine Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
JP4441595B2 (ja) 1998-06-12 2010-03-31 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー インターフェロン誘導性の遺伝子工学的に作製された弱毒ウイルス
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6551820B1 (en) 1998-12-23 2003-04-22 Boyce Thompson Institute For Plant Research Expression of immunogenic hepatitis B surface antigens in transgenic plants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AU4134000A (en) 1999-04-29 2000-11-17 Syngenta Limited Herbicide resistant plants
DE122008000056I1 (de) 1999-07-14 2009-04-09 Sinai School Medicine In vitro-rekonstitution von segmentierten negativstrang-rna-viren
DE60036952T2 (de) 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU2001250856A1 (en) 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
AU2001259211B2 (en) 2000-04-28 2006-07-13 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
US6632620B1 (en) 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
HUE050222T2 (hu) 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP2006521095A (ja) 2003-01-29 2006-09-21 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 寛容誘導標的特異性抗体の生成
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4368594B2 (ja) 2003-02-24 2009-11-18 株式会社インシリコサイエンス タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
ZA200508930B (en) 2003-05-05 2007-03-28 Thompson Boyce Inst Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
CN1833024B (zh) 2003-05-26 2011-08-31 东丽株式会社 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
PL1692265T3 (pl) 2003-11-04 2011-12-30 The Administrators Of The Tulane Educational Fund Sposób zapobiegania fuzji wirus:komórka przez hamowanie działania regionu inicjowania fuzji w wirusach RNA zawierających fuzogenne błonowe białka otoczki klasy I
AU2005248377B2 (en) 2004-05-25 2011-03-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2006040764A2 (en) 2004-10-13 2006-04-20 Protalix Ltd. System and method for production of antibodies in plant cell culture
EP1851238A4 (en) 2005-02-24 2008-12-31 Univ Massachusetts FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20070064857A1 (en) 2005-08-19 2007-03-22 Winterberg Friedwardt M Thermonuclear plasma confinement with thermomagnetic currents generated by nuclear reactions from fusion neutrons
US8098789B2 (en) 2005-09-09 2012-01-17 Wisconsin Alumni Research Foundation Systems and methods for the cyclotron production of iodine-124
US8662363B2 (en) 2005-09-27 2014-03-04 Dennis Williams Golf car accessory
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
AU2006322907B2 (en) 2005-12-06 2012-08-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
KR20080106433A (ko) 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
US20070207171A1 (en) 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US20070262178A1 (en) 2006-05-12 2007-11-15 Ultradent Products, Inc. Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end
AU2007249160B2 (en) 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2035565A4 (en) 2006-06-30 2010-07-21 Novavax Inc METHODS OF ENHANCING THE INCORPORATION OF PROTEINS IN VIRUS-LIKE PARTICLES (VLPs)
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
EP2066345B1 (en) 2006-09-11 2015-02-25 Novartis AG Making influenza virus vaccines without using eggs
US20080075998A1 (en) 2006-09-22 2008-03-27 Tatsumi Ishihara Electrolyte membrane for electrochemical cell and a method of producing the same
US20080085876A1 (en) 2006-10-05 2008-04-10 Schwartz David L Insect sting treatment
EP2174957B1 (en) 2007-06-15 2016-03-16 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
WO2009025770A2 (en) 2007-08-17 2009-02-26 Wyeth A heterologous prime-boost immunization regimen
US9421254B2 (en) 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
FR2921387B1 (fr) * 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
KR20100120157A (ko) 2007-11-27 2010-11-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
CA2708221C (en) 2007-12-06 2017-07-25 Wayne A. Marasco Antibodies against influenza virus and methods of use thereof
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US20100040635A1 (en) 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US8592557B2 (en) 2008-06-17 2013-11-26 Apogenix Gmbh Multimeric TNF receptor fusion proteins and nucleic acids encoding same
EP2294202B1 (en) 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
US9051359B2 (en) 2009-03-30 2015-06-09 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
AU2010247530B2 (en) 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
US8673314B2 (en) 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
HRP20180706T1 (hr) 2009-06-24 2018-06-01 Medicago Inc. Kimerna gripa nalik čestici koja sadrži hemaglutinin
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
JP5463107B2 (ja) 2009-09-14 2014-04-09 独立行政法人国立国際医療研究センター 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬
WO2011044152A1 (en) 2009-10-05 2011-04-14 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Protection against pandemic and seasonal strains of influenza
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011103453A2 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2545074A4 (en) 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
AU2011282423B2 (en) 2010-07-22 2015-05-14 Schrader, Sabariah Cross-protective pathogen protection, methods and compositions thereof
WO2013043729A1 (en) 2011-09-20 2013-03-28 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CN104066446B (zh) 2011-11-28 2017-10-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
US10023629B2 (en) 2012-12-11 2018-07-17 Vib Vzw Anti-influenza antibody
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
IL241552B2 (en) 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
EP3166962B1 (en) 2014-07-10 2019-08-21 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
PE20170291A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5012011722; ＧＥＲＨＡＲＤ　Ｗ: 'ＰＲＯＳＰＥＣＴＳ　ＦＯＲ　ＵＮＩＶＥＲＳＡＬ　ＩＮＦＬＵＥＮＺＡ　ＶＩＲＵＳ　ＶＡＣＣＩＮＥ' ＥＭＥＲＧＩＮＧ　ＩＮＦＥＣＴＩＯＵＳ　ＤＩＳＥＡＳＥＳ Ｖ１２　Ｎ４, 20060401, Ｐ５６９-５７４, ＥＩＤ *
JPN5012011723; ＨＯＲＶＡＴＨ　Ａ: 'Ａ　ＨＥＭＡＧＧＬＵＴＩＮＩＮ-ＢＡＳＥＤ　ＭＵＬＴＩＰＥＰＴＩＤＥ　ＣＯＮＳＴＲＵＣＴ　ＥＬＩＣＩＴＳ　ＥＮＨＡＮＣＥＤ　ＰＲＯＴＥＣＴＩＶＥ　以下備考' ＩＭＭＵＮＯＬＯＧＹ　ＬＥＴＴＥＲＳ Ｖ６０　Ｎ２／０３, 19980201, Ｐ１２７-１３６, ＥＬＳＥＶＩＥＲ　ＢＶ *
JPN5012011724; ＢＩＡＮＣＨＩ　ＥＬＩＳＡＢＥＴＴＡ: 'ＵＮＩＶＥＲＳＡＬ　ＩＮＦＬＵＥＮＺＡ　Ｂ　ＶＡＣＣＩＮＥ　ＢＡＳＥＤ　ＯＮ　ＴＨＥ　ＭＡＴＵＲＡＴＩＯＮＡＬ　ＣＬＥＡＶＡＧＥ　ＳＩＴＥ　ＯＦ　ＴＨＥ　ＨＥＭＡＧＧＬＵＴＩＮＩＮ　ＰＲＥＣＵＲＳＯＲ' ＪＯＵＲＮＡＬ　ＯＦ　ＶＩＲＯＬＯＧＹ Ｖ７９　Ｎ１２, 20050601, Ｐ７３８０-７３８８, ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＳＯＣＩＥＴＹ　ＦＯＲ　ＭＩＣＲＯＢＩＯＬＯＧＹ *
JPN5012011725; ＭＯＫ　Ｈ: 'ＥＮＨＡＮＣＥＭＥＮＴ　ＯＦ　ＴＨＥ　ＣＤ８＋　Ｔ　ＣＥＬＬ　ＲＥＳＰＯＮＳＥ　ＴＯ　Ａ　ＳＵＢＤＯＭＩＮＡＮＴ　ＥＰＩＴＯＰＥ　ＯＦ　ＲＥＳＰＩＲＡＴＯＲＹ　以下備考' ＶＡＣＣＩＮＥ Ｖ２６　Ｎ３７, 20080902, Ｐ４７７５-４７８２, ＥＬＳＥＶＩＥＲ　ＬＴＤ *
JPN6014037659; Ｊ．　Ｇｅｎ．　Ｖｉｒｏｌ． ７７, 1996, ｐ．１４８３-１４８７ *
JPN6014037661; 感染・炎症・免疫 ２９　（２）, 1999, ｐ．１３１-１３３ *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016199557A (ja) * 2009-03-30 2016-12-01 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
JP2013526849A (ja) * 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
JP2016508133A (ja) * 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
US10583188B2 (en) 2012-12-18 2020-03-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US10544207B2 (en) 2013-03-14 2020-01-28 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP7357088B2 (ja) 2013-09-18 2023-10-05 レヴィセプト エルティーディー 融合タンパク質
JP2022068253A (ja) * 2013-09-18 2022-05-09 レヴィセプト エルティーディー 融合タンパク質
JP2020062011A (ja) * 2013-09-18 2020-04-23 レヴィセプト エルティーディーＬｅｖｉｃｅｐｔ Ｌｔｄ 融合タンパク質
JP2016531590A (ja) * 2013-09-18 2016-10-13 レヴィセプト エルティーディーＬｅｖｉｃｅｐｔ Ｌｔｄ 融合タンパク質
JP2017527303A (ja) * 2014-07-17 2017-09-21 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
JP7365378B2 (ja) 2014-07-17 2023-10-19 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
JP2021177766A (ja) * 2014-07-17 2021-11-18 レヴィセプト リミテッド Ｐ７５ｎｔｒニューロトロフィン結合タンパク質の治療的使用
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
JP6996756B2 (ja) 2016-05-19 2022-02-04 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン がんの腫瘍崩壊療法のためのｖｓｖ／ｎｄｖハイブリッドウイルス
JP2019516374A (ja) * 2016-05-19 2019-06-20 クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン がんの腫瘍崩壊療法のためのｖｓｖ／ｎｄｖハイブリッドウイルス
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11865173B2 (en) 2016-06-15 2024-01-09 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US12233123B2 (en) 2016-06-15 2025-02-25 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US12030928B2 (en) 2017-04-07 2024-07-09 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JPWO2019124557A1 (ja) * 2017-12-21 2021-01-28 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
JP7382634B2 (ja) 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP2023539771A (ja) * 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
WO2022071492A1 (ja) * 2020-09-30 2022-04-07 キリンホールディングス株式会社 インフルエンザウイルス抑制用の融合タンパク質およびこれを含む医薬組成物

Also Published As

Publication number Publication date
JP2016199557A (ja) 2016-12-01
US9849172B2 (en) 2017-12-26
AU2017232138A1 (en) 2017-10-12
AU2010234849B2 (en) 2017-06-22
WO2010117786A1 (en) 2010-10-14
US20150297712A1 (en) 2015-10-22
JP2018134107A (ja) 2018-08-30
US9051359B2 (en) 2015-06-09
CA2787099A1 (en) 2010-10-14
EP2413962A1 (en) 2012-02-08
EP3009145A1 (en) 2016-04-20
AU2010234849A1 (en) 2011-11-17
US20100297174A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
US10179806B2 (en) Influenza virus vaccines and uses thereof
US9849172B2 (en) Influenza virus vaccines and uses thereof
EP2536425B1 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
JP2022091775A (ja) インフルエンザウイルスワクチン及びその使用
US10736956B2 (en) Influenza virus vaccination regimens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160209

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160714